Revvity RVTY 深 滬
等待開盤 09-24 09:30:00 美东时间
142.11
-1.200
-0.84%
華盛通- 最 高145.00
- 今 開142.40
- 成交量 224.43万股
- 最 低 140.08
- 昨 收 143.31
- 總市值 158.58亿
- 52周最高 149.52
- 市盈率 靜 68.46
- 換手率 2.01%
- 52周最低 81.15
- 委 比 -3.38%
- 總股本 1.12亿
- 歷史最高 201.83
- 量 比 0.78
- 振 幅 3.43%
- 歷史最低 13.95
- 每 手 1
- 風險率 12.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CFRA downgrades Revvity (RVTY) to a Hold
Revvity received a Hold rating and price target from CFRA analyst on September ...
09-21 16:25
Revvity slips as CFRA downgrades on limited near-term upside
Revvity (RVTY) shares fell on Friday following a five-day winning streak as CFRA downgraded the life sciences company to Hold from Buy, citing a less attractive upside opportunity in the near term aft...
09-19 00:21
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of $16.24 billion. Buying $1000 In RVTY: If an investor had bought $1000 of RVTY stock 15 years ago, it ...
09-17 05:15
美股牛股 | 思佳讯升逾13%，Qorvo升超9%，220亿美元合并进入最后阶段；FPS升逾9%，Q4业绩超预期；Transocean升逾9%，新增8000万美元订单
思佳讯升逾13%，Qorvo升9%，220亿美元合并进入最后阶段；Tempus Al升逾10%，创始人支持Anthropic的AI刹车呼吁>>
09-16 18:36
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
UBS Assumes Revvity at Neutral, Raises Price Target to $140
UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.
09-09 21:57
Revvity to acquire Human Cell Design
Revvity (RVTY) to acquire France-based Human Cell Design, a biotechnology company focused on human cell models for diabetes, obesity and other metabolic diseases. The financial terms were not disclose...
09-09 18:48
Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases
The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026 and ...
09-09 18:09
公司簡介
公司名稱
|
Revvity
|
行業分類
|
--
|
業務描述
|
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
|
CFRA downgrades Revvity (RVTY) to a Hold
Revvity received a Hold rating and price target from CFRA analyst on September ...
09-21 16:25
Revvity slips as CFRA downgrades on limited near-term upside
Revvity (RVTY) shares fell on Friday following a five-day winning streak as CFRA downgraded the life sciences company to Hold from Buy, citing a less attractive upside opportunity in the near term aft...
09-19 00:21
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of $16.24 billion. Buying $1000 In RVTY: If an investor had bought $1000 of RVTY stock 15 years ago, it ...
09-17 05:15
美股牛股 | 思佳讯升逾13%，Qorvo升超9%，220亿美元合并进入最后阶段；FPS升逾9%，Q4业绩超预期；Transocean升逾9%，新增8000万美元订单
思佳讯升逾13%，Qorvo升9%，220亿美元合并进入最后阶段；Tempus Al升逾10%，创始人支持Anthropic的AI刹车呼吁>>
09-16 18:36
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
UBS Assumes Revvity at Neutral, Raises Price Target to $140
UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.
09-09 21:57
Revvity to acquire Human Cell Design
Revvity (RVTY) to acquire France-based Human Cell Design, a biotechnology company focused on human cell models for diabetes, obesity and other metabolic diseases. The financial terms were not disclose...
09-09 18:48
Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases
The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026 and ...
09-09 18:09
派息除權日
|
每股總股息
| 派息日期 |
2026-10-23
|
0.07
|
2026-11-13
|
2026-07-17
|
0.07
|
2026-08-07
|
2026-04-17
|
0.07
|
2026-05-08
|
2026-01-16
|
0.07
|
2026-02-06
|
2025-10-17
|
0.07
|
2025-11-07
|
2025-07-18
|
0.07
|
2025-08-08
|
2025-04-17
|
0.07
|
2025-05-09
|
2025-01-17
|
0.07
|
2025-02-07
|
2024-10-18
|
0.07
|
2024-11-08
|
2024-07-19
|
0.07
|
2024-08-09
|
2024-04-18
|
0.07
|
2024-05-10
|
2024-01-18
|
0.07
|
2024-02-09
|
2023-10-19
|
0.07
|
2023-11-10
|
2023-07-20
|
0.07
|
2023-08-11
|
2023-04-20
|
0.07
|
2023-05-12
|
2023-01-19
|
0.07
|
2023-02-10
|
2022-10-20
|
0.07
|
2022-11-11
|
2022-07-21
|
0.07
|
2022-08-12
|
2022-04-21
|
0.07
|
2022-05-13
|
2022-01-20
|
0.07
|
2022-02-11
|
2021-10-21
|
0.07
|
2021-11-12
|
2021-07-15
|
0.07
|
2021-08-06
|
2021-04-15
|
0.07
|
2021-05-07
|
2021-01-21
|
0.07
|
2021-02-12
|
2020-10-15
|
0.07
|
2020-11-06
|
2020-07-16
|
0.07
|
2020-08-07
|
2020-04-16
|
0.07
|
2020-05-08
|
2020-01-16
|
0.07
|
2020-02-07
|
2019-10-17
|
0.07
|
2019-11-08
|
2019-07-18
|
0.07
|
2019-08-09
|
2019-04-17
|
0.07
|
2019-05-10
|
2019-01-17
|
0.07
|
2019-02-08
|
2018-10-18
|
0.07
|
2018-11-09
|
2018-07-19
|
0.07
|
2018-08-10
|
2018-04-12
|
0.07
|
2018-05-10
|
2018-01-18
|
0.07
|
2018-02-09
|
2017-10-19
|
0.07
|
2017-11-10
|
2017-07-19
|
0.07
|
2017-08-10
|
2017-04-11
|
0.07
|
2017-05-10
|
2017-01-18
|
0.07
|
2017-02-10
|
2016-10-12
|
0.07
|
2016-11-10
|
2016-07-13
|
0.07
|
2016-08-10
|
2016-04-13
|
0.07
|
2016-05-10
|
2016-01-13
|
0.07
|
2016-02-10
|
2015-10-14
|
0.07
|
2015-11-10
|
2015-07-15
|
0.07
|
2015-08-10
|
2015-04-15
|
0.07
|
2015-05-11
|
2015-01-14
|
0.07
|
2015-02-06
|
2014-10-15
|
0.07
|
2014-11-07
|
2014-07-16
|
0.07
|
2014-08-08
|
2014-04-15
|
0.07
|
2014-05-09
|
2014-01-15
|
0.07
|
2014-02-07
|
2013-10-16
|
0.07
|
2013-11-08
|
2013-07-17
|
0.07
|
2013-08-09
|
2013-04-17
|
0.07
|
2013-05-10
|
2013-01-16
|
0.07
|
2013-02-08
|
2012-10-17
|
0.07
|
2012-11-09
|
2012-07-18
|
0.07
|
2012-08-10
|
2011-07-20
|
0.07
|
2011-08-12
|
2011-04-19
|
0.07
|
2011-05-13
|
2011-01-19
|
0.07
|
2011-02-11
|
2010-10-20
|
0.07
|
2010-11-12
|
2010-07-21
|
0.07
|
2010-08-13
|
2010-04-14
|
0.07
|
2010-05-07
|
2010-01-20
|
0.07
|
2010-02-12
|
2009-10-21
|
0.07
|
2009-11-13
|
2009-07-15
|
0.07
|
2009-08-07
|
2009-04-15
|
0.07
|
2009-05-08
|
2009-01-14
|
0.07
|
2009-02-06
|
2008-10-15
|
0.07
|
2008-11-07
|
2008-07-16
|
0.07
|
2008-08-08
|
2008-04-16
|
0.07
|
2008-05-09
|
2008-01-16
|
0.07
|
2008-02-08
|
2007-10-17
|
0.07
|
2007-11-09
|
2007-07-18
|
0.07
|
2007-08-10
|
2007-04-18
|
0.07
|
2007-05-11
|
2007-01-17
|
0.07
|
2007-02-09
|
2006-10-18
|
0.07
|
2006-11-10
|
2006-07-19
|
0.07
|
2006-08-11
|
2006-04-19
|
0.07
|
2006-05-12
|
2006-01-18
|
0.07
|
2006-02-10
|
2005-10-19
|
0.07
|
2005-11-11
|
2005-07-20
|
0.07
|
2005-08-12
|
2005-04-20
|
0.07
|
2005-05-13
|
2005-01-19
|
0.07
|
2005-02-11
|
2004-10-20
|
0.07
|
2004-11-12
|
2004-07-21
|
0.07
|
2004-08-13
|
2004-04-21
|
0.07
|
2004-05-14
|
2004-01-14
|
0.07
|
2004-02-05
|
2003-10-15
|
0.07
|
2003-11-07
|
2003-07-16
|
0.07
|
2003-08-08
|
2003-04-15
|
0.07
|
2003-05-09
|
2003-01-15
|
0.07
|
2003-02-07
|
2002-10-16
|
0.07
|
2002-11-08
|
2002-07-17
|
0.07
|
2002-08-09
|
2002-04-17
|
0.07
|
2002-05-10
|
2002-01-16
|
0.07
|
2002-02-09
|
2001-10-17
|
0.07
|
2001-11-09
|
2001-07-18
|
0.07
|
2001-08-10
|
2001-04-18
|
0.14
|
2001-05-10
|
2001-01-17
|
0.14
|
2001-02-09
|
2000-10-18
|
0.14
|
2000-11-10
|
2000-07-19
|
0.14
|
2000-08-10
|
2000-04-18
|
0.14
|
2000-05-10
|
2000-01-19
|
0.14
|
2000-02-10
|
1999-10-20
|
0.14
|
1999-11-10
|
1999-07-21
|
0.14
|
1999-08-10
|
1999-04-21
|
0.14
|
1999-05-10
|
1999-01-20
|
0.14
|
1999-02-10
|
1998-10-21
|
0.14
|
1998-11-10
|
1998-07-22
|
0.14
|
1998-08-10
|
1998-04-15
|
0.14
|
1998-05-08
|
1998-01-14
|
0.14
|
1998-02-06
|
1997-10-15
|
0.14
|
1997-11-10
|
1997-07-16
|
0.14
|
1997-08-08
|
1997-04-16
|
0.14
|
1997-05-09
|
1997-01-15
|
0.14
|
1997-02-10
|
1996-10-16
|
0.14
|
1996-11-08
|
1996-07-17
|
0.14
|
1996-08-09
|
1996-04-17
|
0.14
|
1996-05-10
|
1996-01-17
|
0.14
|
1996-02-09
|
1995-10-18
|
0.14
|
1995-11-10
|
1995-07-19
|
0.14
|
1995-08-10
|
1995-04-17
|
0.14
|
1995-05-10
|
1995-02-14
|
0.010
|
1995-02-14
|
1995-01-13
|
0.14
|
1995-02-10
|
1994-10-17
|
0.14
|
1994-11-10
|
1994-07-18
|
0.14
|
1994-08-10
|
1994-04-18
|
0.14
|
1994-05-10
|
1994-01-14
|
0.14
|
1994-02-10
|
1993-10-18
|
0.13
|
1993-11-10
|
1993-07-19
|
0.13
|
1993-08-10
|
1993-04-12
|
0.13
|
1993-05-07
|
1993-01-15
|
0.13
|
1993-02-10
|
1992-10-19
|
0.13
|
1992-11-10
|
1992-07-13
|
0.13
|
1992-08-07
|
1992-04-10
|
0.25
|
1992-05-08
|
1992-01-13
|
0.23
|
1992-02-07
|
1991-10-11
|
0.21
|
1991-11-08
|
1991-07-14
|
0.21
|
1991-08-08
|
1991-04-14
|
0.21
|
1991-05-09
|
1991-01-14
|
0.21
|
1991-02-08
|
1990-10-15
|
0.19
|
1990-11-09
|
1990-07-15
|
0.19
|
1990-08-09
|
1990-04-15
|
0.19
|
1990-05-09
|
1990-01-12
|
0.19
|
1990-02-09
|
1989-10-16
|
0.17
|
1989-11-10
|
1989-07-16
|
0.17
|
1989-08-09
|
1989-04-16
|
0.17
|
1989-05-09
|
1989-01-13
|
0.17
|
1989-02-10
|
1988-10-25
|
0.15
|
1988-11-10
|
1988-07-17
|
0.15
|
1988-08-09
|
1988-04-17
|
0.15
|
1988-05-09
|
1988-01-15
|
0.15
|
1988-02-10
|
1987-10-19
|
0.14
|
1987-11-10
|
1987-07-19
|
0.14
|
1987-08-06
|
1987-04-10
|
0.14
|
1987-05-07
|
1987-01-16
|
0.14
|
1987-02-10
|
1986-10-10
|
0.13
|
1986-11-07
|
1986-07-13
|
0.13
|
1986-08-07
|
1986-04-14
|
0.13
|
1986-05-08
|
1986-01-13
|
0.13
|
1986-02-07
|
1985-10-11
|
0.12
|
1985-11-08
|
1985-07-15
|
0.12
|
1985-08-09
|
1985-04-15
|
0.12
|
1985-05-10
|
1985-01-14
|
0.12
|
1985-02-08
|
1984-10-15
|
0.10
|
1984-11-09
|
1984-07-16
|
0.10
|
1984-08-10
|
1984-04-13
|
0.10
|
1984-05-10
|
1984-01-16
|
0.10
|
1984-02-10
|
1983-10-17
|
0.09
|
1983-11-10
|
1983-07-18
|
0.09
|
1983-08-10
|
1983-04-18
|
0.09
|
1983-05-10
|
1983-01-17
|
0.09
|
1983-02-10
|
1982-10-18
|
0.08
|
1982-11-10
|
1982-07-12
|
0.08
|
1982-08-02
|
1982-04-12
|
0.08
|
1982-05-03
|
1982-01-04
|
0.16
|
1982-01-08
|
1981-10-09
|
0.13
|
1981-11-02
|
1981-07-13
|
0.13
|
1981-08-03
|
1981-04-10
|
0.13
|
1981-05-01
|
1981-01-12
|
0.13
|
1981-02-02
|
1980-10-10
|
0.10
|
1980-11-03
|
1980-07-14
|
0.10
|
1980-08-01
|
1980-04-07
|
0.10
|
1980-05-01
|
1980-01-07
|
0.20
|
1980-02-01
|
1979-10-05
|
0.15
|
1979-11-01
|
1979-07-09
|
0.15
|
1979-08-01
|
1979-04-06
|
0.15
|
1979-05-01
|
1979-01-08
|
0.15
|
1979-02-01
|
1978-10-06
|
0.11
|
1978-11-01
|
1978-07-10
|
0.11
|
1978-08-01
|
1978-04-10
|
0.11
|
1978-05-01
|
1978-01-09
|
0.09
|
1978-02-01
|
1977-10-07
|
0.09
|
1977-11-01
|
1977-08-08
|
0.09
|
1977-09-01
|
1977-05-09
|
0.09
|
1977-06-01
|
